Locoregional Recurrence after Mastectomy in Breast Cancer Patients with 1-3 Positive Lymph Nodes Treated with Modern Systemic Therapy

2011 ◽  
Vol 81 (2) ◽  
pp. S91-S92
Author(s):  
R.D. Tendulkar ◽  
S. Rehman ◽  
M. Shukla ◽  
C.A. Reddy
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Locoregional Recurrence ◽  
Breast Cancer Patients ◽  
Positive Lymph Nodes

Locoregional recurrence and metastasis in the long-term follow-up of postmastectomy breast cancer patients with T1–T2 tumours and one to three positive lymph nodes

2004 ◽  
Vol 6 (6) ◽  
pp. 341-346 ◽  
Author(s):  
Antonio Piñero Madrona ◽  
Juan Salinas Ramos ◽  
Julián Illana Moreno ◽  
Joaquín Sola Pérez ◽  
Manuel Canteras Jordana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Locoregional Recurrence ◽  
Breast Cancer Patients ◽  
Long Term Follow Up ◽  
Positive Lymph Nodes

scholarly journals Postmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients

2004 ◽  
Vol 12 (1) ◽  
pp. 39-43
Author(s):  
Danijela Scepanovic ◽  
Nada Bajic ◽  
Jovan Babic
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Locoregional Recurrence ◽  
Disease Free Survival ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

BACKGROUND: Postmastectomy radiotherapy has been the topic for many debates over several years about its role on locoregional control as well as overall survival in premenopausal and postmenopausal breast cancer patients. METHODS: From 1994 till 1999, 233 patients underwent modified radical mastectomy for breast cancer. Among them there was 92 premenopausal patients (median age was 44 years) and 141 postmenopausal patients (median age was 60 years). Traditional prognostic factors were used to assess risk of locoregional recurrence: 84 patients were node-negative, 71 patients had 1 to 3 lymph nodes positive, and 71 patients had 4 and more positive lymph nodes; 103 patients had tumor less than 3 cm diameter and 130 patients had tumors grater than 3 cm. According to this, postmastectomy radio- therapy was applied in 125 patients of whom 117 patients (94%) had also adjuvant systemic therapy (chemotherapy and/or hormonal therapy). RESULTS: The locoregional recurrence was observed in 42 patients while 191 patients were free of (median follow-up time was 49 months). Locoregional recurrence developed in 10 patients who had postmastectomy radiotherapy and in 32 patients who did not had postmastectomy radiotherapy (p=0.0001). In the group of patients with locoregional recurrence event 5-year overall survival was 28% while 70% in the group of patients free of (p=0.00001). There was statistically significant advantage for post- mastectomy radiotherapy in the group of patients with 1 to 3 positive lymph nodes as well as for 4 and more positive lymph nodes group (p=0.0008). In addition there was statistically significant difference among postmastectomy radiotherapy group and no postmastectomy radiotherapy group for disease free survival (74% vs. 50%, 5-year disease free survival, p=0.0001) and overall survival (71% vs. 53%, 5-year overall survival, p=0.0422). CONCLUSION: Postmastectomy radiotherapy reduces locoregional recurrence rate and improves overall survival in premenopausal and postmenopausal breast cancer patients with tumors grater than 3cm diameter and positive axillary lymph nodes.

Postmastectomy Radiotherapy in T1–2 Female Breast Cancer Patients with 1–3 Positive Axillary Lymph Nodes: A Propensity Score Matched SEER Analysis

2021 ◽  
Author(s):  
Gang Xu ◽  
Shanshan Bu ◽  
Xiushen Wang ◽  
Hong Ge
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Female Breast ◽  
Positive Lymph Nodes

Abstract Purpose The application of postmastectomy radiotherapy (PMRT) in T1–2 female breast cancer patients with 1–3 positive lymph nodes has been controversial. We sought to determine the survival benefits of PMRT in the patients with T1–2 and 1–3 positive nodes. Methods A retrospective study using the Surveillance, Epidemiology, and End Results (SEER) Regs Custom Data (with additional treatment fields) from 2001 to 2011 was performed. Patients who received PMRT were matched by the propensity score with patients who did not receive PMRT. The Overall survival (OS) and breast cancer-specific survival (BCSS) were analyzed. Results We identified 56,725 female breast cancer patients with T1–2 and 1–3 positive nodes, and 18,646 patients were included in the analysis. After propensity score matching (1:1), with a median follow-up of 116 months, PMRT showed an increase in the OS (P = 0.018) but had no effect on the BCSS. The 10-year OS rates were 76.8% and 74.4%, and the 10-year BCSS rates were 82.8% and 82.2% for the patients who received and who did not receive PMRT, respectively. Only patients with 3 positive nodes could gain the benefit of PMRT for BCSS. Conclusion PMRT for patients with T1–2 and 1–3 positive lymph nodes could increase the 10-year OS, and had no effect on the 10-year BCSS. Subgroup analysis indicated that only patients with 3 positive lymph nodes could benefit from PMRT for both the OS and BCSS.

Sign in / Sign up

Export Citation Format

Share Document